Figure 6.

Reduced angiogenesis in ADV.mEnd-treated tumors. (A–F) Decreased tumor vascularization could be demonstrated in all ADV.mEnd-treated tumors [LLC, hematoxylin/eosin (A); JC, hematoxylin/eosin (C); JC, ICAM-1 (E)] as compared with the controls [LLC, hematoxylin/eosin (B); JC, hematoxylin/eosin (D); JC, ICAM-1 (F)]. (D₁) Markedly increased angiogenesis also could be observed at the border zone between tumor and surrounding tissue in the control group of the JC tumors. (A–F, ×100; D₁, ×200.)